Provided by Tiger Trade Technology Pte. Ltd.

Hillhouse Capital Related

450.903
-2.583-0.57%
Number of Gainers:8
Number of Losers:37
Number of Flat:6
PE:- -
High:455.223
Open:453.447
Low:445.681
Close:453.486
Volume:529.76M
Turnover:10.46B
Market Cap:2.85T
Float Cap:1.98T

Loading ...

AK Medical Files HKEX Next-Day Disclosure Return on Share Repurchase for Cancellation

Reuters
·
Sep 11

ZYLOXTB Repurchases 55,000 Shares for HK$1.12 Million on September 11

Stock News
·
Sep 11

Hansoh Pharmaceutical Says Risvutatug Rezetecan Injection Included in NMPA Priority Review

Reuters
·
Sep 11

Zylox-Tonbridge Files HKEX Next-Day Disclosure Return on Share Buyback for Cancellation

Reuters
·
Sep 11

Xinyi Energy Files HKEX Next-Day Disclosure Return Disclosing Share Repurchase for Cancellation

Reuters
·
Sep 11

Shandong Boan Biotech Files HKEX Next-Day Disclosure Reporting Share Repurchase for Treasury Shares

Reuters
·
Sep 11

Venus Medtech Schedules Extraordinary General Meeting

Reuters
·
Sep 11

Sunac Services Files HKEX Next-Day Disclosure Return After Share Buyback for Cancellation

Reuters
·
Sep 11

LifeTech Swings to RMB 34.28 Million Net Loss in 1H FY26; Revenue Drops 11.2% to RMB 600.83 Million

Reuters
·
Sep 11

Hong Kong Stocks Fall as Oil Extends Rally; Venus Medtech Gains

MT Newswires Live
·
Sep 11

Daiwa Cuts HAIDILAO Target Price to HK$11.3, Maintains Outperform Rating

Stock News
·
Sep 11

Hansoh Pharma's Investigational Therapy for Small Cell Lung Cancer Granted Priority Review by Chinese Regulator

Stock News
·
Sep 11

China Resources Beer (Holdings) Stock Slips 1.8% in Hong Kong

Dow Jones
·
Sep 11

Haidilao International Holding Stock Rallies 1.5% in Hong Kong

Dow Jones
·
Sep 11

Hansoh Pharmaceutical Group Stock Slides 1.9% in Hong Kong

Dow Jones
·
Sep 11

Hansoh Pharma Says NMPA Grants Priority Review for HS-20093 in Small Cell Lung Cancer

Reuters
·
Sep 11

Hansoh Pharmaceutical - Risvutatug Rezetecan for Injection Included in Nmpa Priority Review for Small Cell Lung Cancer

THOMSON REUTERS
·
Sep 11

MEDCAPTAIN's Hong Kong IPO: A Medical Device Empire Built on Acquisitions Faces Multiple Headwinds

Deep News
·
Sep 11

Morgan Stanley Sees Undervalued Long-Term Potential in Meituan's In-Store Services; Maintains Overweight Rating with HK$110 Target

Stock News
·
Sep 11

HK-Listed GenScript Biotech Drops on Discounted Share Sale

Reuters
·
Sep 11